How innate immune mechanisms contribute to antibody-enhanced viral infections

Clinical and Vaccine Immunology

Volumn 17, Issue 12, 2010, Pages 1829-1835

  Ubol, Sukathida ^a   Halstead, Scott B ^b,c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b International Vaccine Institute   (South Korea)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; B7 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; INTERFERON; MEASLES VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; TOLL LIKE RECEPTOR;

CELL MATURATION; DENDRITIC CELL; DENGUE; DISEASE SEVERITY; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNIZATION; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; SHORT SURVEY; TH2 CELL; VIRUS ENTRY; VIRUS INFECTION; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, BLOCKING; ANTIBODY-DEPENDENT ENHANCEMENT; HUMANS; IMMUNE TOLERANCE; IMMUNITY, INNATE; VIRAL VACCINES; VIRUS DISEASES; VIRUSES;

EID: 78649820026     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00316-10     Document Type: Short Survey

References (83)

1. Anderson, C. F., and D. M. Mosser. 2002. Cutting edge: biasing immune responses by directing antigen to macrophage Fc gamma receptors. J. Immunol. 168:3697-3701.
2. Balsitis, S. J., J. Coloma, G. Castro, A. Alava, D. Flores, J. H. McKerrow, P. R. Beatty, and E. Harris. 2009. Tropism of dengue virus in mice and humans defined by viral nonstructural protein 3-specific immunostaining. Am. J. Trop. Med. Hyg. 80:416-424.
3. Barbey-Martin, C., B. Gigant, T. Bizebard, L. J. Calder, S. A. Wharton, J. J. Skehel, and M. Knossow. 2002. An antibody that prevents the hemagglutinin low pH fusogenic transition. Virology 294:70-74. (Pubitemid 34921290)
4. Bethell, D. B., K. Flobbe, X. T. Cao, N. P. Day, T. P. Pham, W. A. Buurman, M. J. Cardosa, N. J. White, and D. Kwiatkowski. 1998. Pathophysiologic and prognostic role of cytokines in dengue hemorrhagic fever. J. Infect. Dis. 177:778-782.
5. Boonnak, K., B. M. Slike, T. H. Burgess, R. M. Mason, S. J. Wu, P. Sun, K. Porter, I. F. Rudiman, D. Yuwono, P. Puthavathana, and M. A. Marovich. 2008. Role of dendritic cells in antibody-dependent enhancement of dengue virus infection. J. Virol. 82:3939-3951.
6. Brokstad, K. A., R. J. Cox, D. Major, J. M. Wood, and L. R. Haaheim. 1995. Cross-reaction but no avidity change of the serum antibody response after influenza vaccination. Vaccine 13:1522-1528.
7. Buser, F. 1967. Side reaction to measles vaccination suggesting the Arthus phenomenon. N. Engl. J. Med. 277:250-251.
8. Chareonsirisuthigul, T., S. Kalayanarooj, and S. Ubol. 2007. Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells. J. Gen. Virol. 88:365-375.
9. Chaturvedi, U. C., R. Raghupathy, A. S. Pasca, E. A. Elbishbishi, R. Agarwal, R. Nagar, A. Misra, S. Kapoor, A. Mathur, M. Khan, and F. Azizieh. 1999. Shift from a Th1-type response to Th-type in dengue haemorrhagic fever. Curr. Sci. 76:63-69.
10. Chen, L. C., H. Y. Lei, C. C. Liu, S. C. Shiesh, S. H. Chen, H. S. Liu, Y. S. Lin, S. T. Wang, H. W. Shyu, and T. M. Yeh. 2006. Correlation of serum levels of macrophage migration inhibitory factor with disease severity and clinical outcome in dengue patients. Am. J. Trop. Med. Hyg. 74:142-147.
11. Chin, J., R. L. Magoffin, L. A. Shearer, J. H. Schieble, and E. H. Lennette. 1969. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am. J. Epidemiol. 89:449-463.
12. Cohen, S. N., and S. B. Halstead. 1966. Shock associated with dengue infection. I. Clinical and physiologic manifestations of dengue hemorrhagic fever in Thailand, 1964. J. Pediatr. 68:448-456.
13. Dejnirattisai, W., A. Jumnainsong, N. Onsirisakul, P. Fitton, S. Vasanawathana, W. Limpitikul, C. Puttikhunt, C. Edwards, T. Duangchinda, S. Supasa, K. Chawansuntati, P. Malasit, J. Mongkolsapaya, and G. Screaton. 2010. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328:745-748.
14. Delgado, M. F., S. Coviello, A. C. Monsalvo, G. A. Melendi, J. Z. Hernandez, J. P. Batalle, L. Diaz, A. Trento, H. Y. Chang, W. Mitzner, J. Ravetch, J. A. Melero, P. M. Irusta, and F. P. Polack. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat. Med. 15:34-41.
15. de Swart, R. L., B. G. van den Hoogen, T. Kuiken, S. Herfst, G. van Amerongen, S. Yuksel, L. Sprong, and A. D. Osterhaus. 2007. Immunization of macaques with formalin-inactivated human metapneumovirus induces hypersensitivity to hMPV infection. Vaccine 25:8518-8528.
16. Dubischar-Kastner, K., S. Eder, V. Buerger, G. Gartner-Woelfl, A. Kaltenboeck, E. Schuller, E. Tauber, and C. Klade. 2010. Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO, IC51. Vaccine 28:5197-5202.
17. Durbin, A. P., M. J. Vargas, K. Wanionek, S. N. Hammond, A. Gordon, C. Rocha, A. Balmaseda, and E. Harris. 2008. Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology 376:429-435.
18. Fleury, D., B. Barrere, T. Bizebard, R. S. Daniels, J. J. Skehel, and M. Knossow. 1999. A complex of influenza hemagglutinin with a neutralizing antibody that binds outside the virus receptor binding site. Nat. Struct. Biol. 6:530-534.
19. Francis, T., Jr. 1955. Evaluation of the 1954 poliomyelitis vaccine field trial; further studies of results determining the effectiveness of poliomyelitis vaccine (Salk) in preventing paralytic poliomyelitis. JAMA 158:1266-1270.
20. Fulginiti, F. A., J. J. Eller, A. W. Downie, and C. H. Kempe. 1967. Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines. JAMA 202:1075-1080.
21. Gimenez, H. B., S. Chisholm, J. Dornan, and P. Cash. 1996. Neutralizing and enhancing activities of human respiratory syncytial virus-specific antibodies. Clin. Diagn. Lab. Immunol. 3:280-286.
22. Gollins, S. W., and J. S. Porterfield. 1985. Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry. J. Gen. Virol. 66:1969-1982.
23. Gollins, S. W., and J. S. Porterfield. 1984. Flavivirus infection enhancement in macrophages: radioactive and biological studies on the effect of antibody on virus fate. J. Gen. Virol. 65:1261-1272.
24. Green, S., D. W. Vaughn, S. Kalayanarooj, S. Nimmannitya, S. Suntayakorn, A. Nisalak, A. L. Rothman, and F. A. Ennis. 1999. Elevated plasma interleukin-10 levels in acute dengue correlate with disease severity. J. Med. Virol. 59:329-334.
25. Guy, B., V. Barban, N. Mantel, M. Aguirre, S. Gulia, J. Pontvianne, T. M. Jourdier, L. Ramirez, V. Gregoire, C. Charnay, N. Burdin, R. Dumas, and J. Lang. 2009. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am. J. Trop. Med. Hyg. 80:302-311.
26. Halstead, S. B. 1982. Immune enhancement of viral infection. Prog. Allergy 31:301-364.
27. Halstead, S. B. 2003. Neutralization and antibody-dependent enhancement of dengue viruses, p. 422-467. In T. J. Chambers and T. P. Monath (ed.), The flaviviruses: pathogenesis and immunity, vol. 60. Elsevier Academic Press, New York, NY.
28. Halstead, S. B., J. Chow, and N. J. Marchette. 1973. Immunologic enhancement of dengue virus replication. Nat. New Biol. 243:24-26.
29. Halstead, S. B., S. Nimmannitya, C. Yamarat, and P. K. Russell. 1967. Hemorrhagic fever in Thailand; recent knowledge regarding etiology. Jpn. J. Med. Sci. Biol. 20(Suppl.):96-103.
30. Halstead, S. B., and E. J. O'Rourke. 1977. Antibody-enhanced dengue virus infection in primate leukocytes. Nature 265:739-741.
31. Halstead, S. B., and E. J. O'Rourke. 1977. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146:201-217.
32. Halstead, S. B., E. J. O'Rourke, and A. C. Allison. 1977. Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection. J. Exp. Med. 146:218-228.
33. Halstead, S. B., M. C. Tom, and J. L. Elm, Jr. 1981. In vitro virulence marker: growth of dengue-2 virus in human leukocyte suspension cultures. Infect. Immun. 31:102-106.
34. Hawkes, R. A. 1964. Enhancement of the infectivity of arboviruses by specific antisera produced in domestic fowls. Aust. J. Exp. Biol. Med. Sci. 42:465-482.
35. Hawkes, R. A., and K. J. Lafferty. 1967. The enhancement of virus infectivity by antibody. Virology 33:250-261.
36. Hoke, C. H., Jr., A. Nisalak, N. Sangawhipa, S. Jatanasen, T. Laorakpongse, B. L. Innis, S. Kotchasenee, J. B. Gingrich, J. Latendresse, K. Fukai, et. al. 1988. Protection against Japanese encephalitis by inactivated vaccines. N. Engl. J. Med. 319:608-614.
37. Huisman, W., B. E. Martina, G. F. Rimmelzwaan, R. A. Gruters, and A. D. Osterhaus. 2009. Vaccine-induced enhancement of viral infections. Vaccine 27:505-512.
38. Jessie, K., M. Y. Fong, S. Devi, S. K. Lam, and K. T. Wong. 2004. Localization of dengue virus in naturally infected human tissues, by immunohistochemistry and in site hybridization. J. Infect. Dis. 189:1411-1418.
39. Johnson, T. R., S. Rao, R. A. Seder, M. Chen, and B. S. Graham. 2009. TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity. Vaccine 27:3045-3052.
40. Kim, H. W., J. G. Canchola, C. D. Brandt, G. Pyles, K. Chanock, K. Jensen, and R. H. Parrott. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89:422-434.
41. Kimman, T. G., L. A. Cornelissen, R. J. Moormann, J. M. Rebel, and N. Stockhofe-Zurwieden. 2009. Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccinology. Vaccine 27:3704-3718.
42. Kliks, S., and S. B. Halstead. 1980. An explanation for enhanced virus plaque formation in chick embryo cells. Nature 285:504-505.
43. Kliks, S., and S. B. Halstead. 1983. Role of antibodies and host cells in plaque enhancement of Murray Valley encephalitis virus. J. Virol. 46:394-404.
44. Kliks, S. C., A. Nisalak, W. E. Brandt, L. Wahl, and D. S. Burke. 1989. Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am. J. Trop. Med. Hyg. 40:444-451.
45. Knossow, M., M. Gaudier, A. Douglas, B. Barrere, T. Bizebard, C. Barbey, B. Gigant, and J. J. Skehel. 2002. Mechanism of neutralization of influenza virus infectivity by antibodies. Virology 302:294-298.
46. Libraty, D. H., L. P. Acosta, V. Tallo, E. Segubre-Mercado, A. Bautista, J. A. Potts, R. G. Jarman, I. K. Yoon, R. V. Gibbons, J. D. Brion, and R. Z. Capeding. 2009. A prospective nested case-control study of dengue in infants: rethinking and refining the antibody-dependent enhancement dengue hemorrhagic fever model. PLoS Med. 6:e1000171.
47. Libraty, D. H., T. P. Endy, H. S. Houng, S. Green, S. Kalayanarooj, S. Suntayakorn, W. Chansiriwongs, D. W. Vaughn, A. Nisalak, F. A. Ennis, and A. L. Rothman. 2002. Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J. Infect. Dis. 185:1213-1221.
48. Lidbury, B. A., and S. Mahalingam. 2000. Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J. Virol. 74:8376-8381.
49. Linn, M. L., J. G. Aaskov, and A. Suhrbier. 1996. Antibody-dependent enhancement and persistence in macrophages of an arbovirus associated with arthritis. J. Gen. Virol. 77:407-411.
50. Modhiran, N., S. Kalayanarooj, and S. Ubol. Subversion of innate defenses by the interplay between DENV and preexisting enhancing antibodies: TLRs signaling collapse. PLoS Negl. Trop. Dis., in press.
51. Moghaddam, A., W. Olszewska, B. Wang, J. S. Tregoning, R. Helson, Q. J. Sattentau, and P. J. Openshaw. 2006. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat. Med. 12:905-907.
52. Murphy, B. R., and E. E. Walsh. 1988. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J. Clin. Microbiol. 26:1595-1597.
53. Navarro-Sanchez, E., P. Despres, and L. Cedillo-Barron. 2005. Innate immune responses to dengue virus. Arch. Med. Res. 36:425-435.
54. Nguyen, T. H., H. Y. Lei, T. L. Nguyen, Y. S. Lin, K. J. Huang, B. L. Le, C. F. Lin, T. M. Yeh, Q. H. Do, T. Q. Vu, L. C. Chen, J. H. Huang, T. M. Lam, C. C. Liu, and S. B. Halstead. 2004. Dengue hemorrhagic fever in infants: a study of clinical and cytokine profiles. J. Infect. Dis. 189:221-232.
55. Olsen, C., and F. Scott. 1993. Evaluation of antibody-dependent enhancement of feline infectious peritonitis virus infectivity using in situ hybridization. Microb. Pathog. 14:275-285.
56. Olszewska, W., Y. Suezer, G. Sutter, and P. J. Openshaw. 2004. Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. Vaccine 23:215-221.
57. Pedersen, N. C. 2009. A review of feline infectious peritonitis virus infection: 1963-2008. J. Feline Med. Surg. 11:225-258.
58. Pedersen, N. C., and J. F. Boyle. 1980. Immunologic phenomena in the effusive form of feline infectious peritonitis. Am. J. Vet. Res. 41:868-876.
59. Polack, F. P., P. G. Auwaerter, S. H. Lee, H. C. Nousari, A. Valsamakis, K. M. Leiferman, A. Diwan, R. J. Adams, and D. E. Griffin. 1999. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat. Med. 5:629-634.
60. Polack, F. P., S. J. Hoffman, G. Crujeiras, and D. E. Griffin. 2003. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat. Med. 9:1209-1213.
61. Polack, F. P., M. N. Teng, P. L. Collins, G. A. Prince, M. Exner, H. Regele, D. D. Lirman, R. Rabold, S. J. Hoffman, C. L. Karp, S. R. Kleeberger, M. Wills-Karp, and R. A. Karron. 2002. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196:859-865.
62. Ponnuraj, E. M., J. Springer, A. R. Hayward, H. Wilson, and E. A. Simoes. 2003. Antibody-dependent enhancement, a possible mechanism in augmented pulmonary disease of respiratory syncytial virus in the bonnet monkey model. J. Infect. Dis. 187:1257-1263.
63. Prince, G. A., A. B. Jenson, V. G. Hemming, B. R. Murphy, E. E. Walsh, R. L. Horswood, and R. M. Chanock. 1986. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J. Virol. 57:721-728.
64. Pulendran, B. 2009. Learning immunology from the yellow fever vaccine: innate immunity to systems vaccinology. Nat. Rev. Immunol. 9:741-747.
65. Robinson, W. E., Jr., D. C. Montefiori, D. H. Gillespie, and W. M. Mitchell. 1989. Complement-mediated, antibody-dependent enhancement of HIV-1 infection in vitro is characterized by increased protein and RNA syntheses and infectious virus release. J. Acquir. Immune Defic. Syndr. 2:33-42.
66. Rodenhuis-Zybert, I. A., H. M. van der Schaar, J. M. D. Voorham, H. van der Ende-Metselaar, H. Y. Lei, J. Wilschut, and J. M. Smit. 2010. Immature dengue virus: a veiled pathogen? PLoS Pathog. 6:e1000718.
67. Sauter, N. K., M. D. Bednarski, B. A. Wurzburg, J. E. Hanson, G. M. Whitesides, J. J. Skehel, and D. C. Wiley. 1989. Hemagglutinins from two influenza virus variants bind to sialic acid derivatives with millimolar dissociation constants: a 500-MHz proton nuclear magnetic resonance study. Biochemistry 28:8388-8396.
68. Shresta, S., J. L. Kyle, H. M. Snider, M. Basavapatna, P. R. Beatty, and E. Harris. 2004. Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J. Virol. 78:2701-2710. (Pubitemid 38314329)
69. Shresta, S., K. L. Sharar, D. M. Prigozhin, H. M. Snider, P. R. Beatty, and E. Harris. 2005. Critical roles for both STAT1-dependent and STAT1-independent pathways in the control of primary dengue virus infection in mice. J. Immunol. 175:3946-3954. (Pubitemid 41292056)
70. Simmons, C. P., T. N. Chau, T. T. Thuy, N. M. Tuan, D. M. Hoang, N. T. Thien, B. Lien le, N. T. Quy, N. T. Hieu, T. T. Hien, C. McElnea, P. Young, S. Whitehead, N. T. Hung, and J. Farrar. 2007. Maternal antibody and viral factors in the pathogenesis of dengue virus in infants. J. Infect. Dis. 196:416-424.
71. Simmons, C. P., S. Popper, C. Dolocek, T. N. Chau, M. Griffiths, N. T. Dung, T. H. Long, D. M. Hoang, N. V. Chau, T. T. Thao le, T. T. Hien, D. A. Relman, and J. Farrar. 2007. Patterns of host genome-wide gene transcript abundance in the peripheral blood of patients with acute dengue hemorrhagic fever. J. Infect. Dis. 195:1097-1107.
72. Suhrbier, A., and M. La Linn. 2003. Suppression of antiviral responses by antibody-dependent enhancement of macrophage infection. Trends Immunol. 24:165-168. (Pubitemid 36412099)
73. Sullivan, N. J. 2001. Antibody-mediated enhancement of viral disease. Curr. Top. Microbiol. Immunol. 260:145-169.
74. Tirado, S. M., and K. J. Yoon. 2003. Antibody-dependent enhancement of virus infection and disease. Viral Immunol. 16:69-86.
75. Tregoning, J. S., Y. Yamaguchi, J. Harker, B. Wang, and P. J. Openshaw. 2008. The role of T cells in the enhancement of respiratory syncytial virus infection severity during adult reinfection of neonatally sensitized mice. J. Virol. 82:4115-4124.
76. Ubol, S., P. Masrinoul, J. Chaijaruwanich, S. Kalayanarooj, T. Charoensirisuthikul, and J. Kasisith. 2008. Differences in global gene expression in peripheral blood mononuclear cells indicate a significant role of the innate responses in progression of dengue fever but not dengue hemorrhagic fever. J. Infect. Dis. 197:1459-1467.
77. Ubol, S., W. Phuklia, S. Kalayanarooj, and N. Modhiran. 2010. Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J. Infect. Dis. 201:923-935.
78. Vaughn, D. W., S. Green, S. Kalayanarooj, B. L. Innis, S. Nimmannitya, S. Suntayakorn, T. P. Endy, B. Raengsakulrach, A. L. Rothman, F. A. Ennis, and A. Nisalak. 2000. Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J. Infect. Dis. 181:2-9.
79. Vennema, H., R. J. DeGroot, D. A. Harbour, M. Dalderup, T. Gruffydd- Jones, M. C. Horzinek, and W. J. M. Spaan. 1990. Early death after feline infectious peritonitis challenge due to recombinant vaccinia virus immunization. J. Virol. 64:1407-1409.
80. Vennema, H., A. Poland, J. Foley, and N. C. Pedersen. 1998. Feline infectious peritonitis viruses arise by mutation from endemic feline enteric coronaviruses. Virology 243:150-157.
81. Weiss, R. C., and F. W. Scott. 1981. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp. Immunol. Microbiol. Infect. Dis. 4:175-188.
82. Wu, S. J., G. Grouard-Vogel, W. Sun, J. R. Mascola, E. Brachtel, R. Putvatana, M. K. Louder, L. Filgueira, M. A. Marovich, H. K. Wong, A. Blauvelt, G. S. Murphy, M. L. Robb, B. L. Innes, D. L. Birx, C. G. Hayes, and S. S. Frankel. 2000. Human skin Langerhans cells are targets of dengue virus infection. Nat. Med. 6:816-820.
83. Yoon, K. J., L. L. Wu, J. J. Zimmerman, H. T. Hill, and K. B. Platt. 1996. Antibody-dependent enhancement (ADE) of porcine reproductive and respiratory syndrome virus (PRRSV) infection in pigs. Viral Immunol. 9:51-63.